Dimerix Limited · ASX:DXB
Dimerix — Ausbiotech 2019 Conference
21 slides from Dimerix's conference presentation, Oct 30, 2019
Slide 1: Ausbiotech 2019 Conference Presentation announcement
For Immediate Release Ausbiotech 2019 Conference Presentation For personal use only MELBOURNE, Australia, 30 October 2019: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company, is pleased to provide a copy of the presentation from the Ausbiotech 2019 Conference today. For further i
Slide 2: About FSGS and DMX-700
FSGS is a serious and rare disease that attacks the kidney’s filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and kidney failure and for which there is a recognised medical need for a new or improved treatment. FSGS affects both children and adults. DMX-200
Slide 3: Target indications: a hot area for big pharma?
Dimerix Target indications: a hot area for big pharma? Ausbiotech 30 October 2019
Slide 4: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 5: Share price performance
For personal use only Share price performance *does not include R&D tax rebate of $1.2 million received 3
Slide 6: Three product candidates in active development
For personal use only Three product candidates in active development: • DMX-200 in two Phase 2 studies: 1. Focal Segmental Glomerulosclerosis (FSGS) Clinical read-out for both studies 2. Diabetic Kidney Disease in Q2 2020 • DMX-700 preparing for clinical studies: 3. Chronic Obstructive Pulmonary Dis
Slide 7: A pipeline of drugs identified using Receptor-HIT
A pipeline of drugs identified using Receptor-HIT Targeting different GPCR receptor pairs Dimerix Strategic Fit Dimerix is developing a commercial pipeline of drugs for G Protein-Coupled Receptors (GPCR) largely targeting chemokine pathway diseases with a clear unmet need Dimerix can utilise its cur
Slide 8: For personal use only
For personal use only
Slide 9: For personal use only
For personal use only • • • • • • 7
Slide 10: DMX-200 in Diabetic Kidney Disease (DKD)
For personal use only DMX-200 in Diabetic • Kidney Disease (DKD) Progressive disease, leading to kidney failure and blood dialysis Study period 1 Washout Study Period 2 12 weeks 6 weeks 12 weeks 23 million diagnosed Results diabetics in the US Group 1 (n=20) DMX-200 Placebo Diabetes incidence Group
Slide 11: DMX-200 in Focal Segmental Glomerulosclerosis (FSGS)
For personal use only DMX-200 in Focal Segmental • Glomerulosclerosis (FSGS) Faster path to market with set market exclusivity period Serious and rare kidney disease: orphan indication Study period 1 Washout Study Period 2 16 weeks 6 weeks 16 weeks ~210,000 individuals Results affected globally Grou
Slide 12: Regulatory pathway 505(b)(1) for DMX-200
505(b)(1) regulatory pathway For personal use only for New Chemical Entity (NCE) IND submission planned planned in 2020, post Phase 2 data read-out Pre-IND meeting scheduled for November 2019 for FSGS Phase 3 plan Significant literature based non-clinical data available to support submission Pre-IND
Slide 13: Introduction to DMX-700
Introduction to DMxX-700
Slide 14: DMX-700 in Chronic Obstructive Pulmonary Disease (COPD)
For personal use only DMX-700 in Chronic Obstructive Pulmonary Disease (COPD) Progressive & life- threatening lung disease affecting individuals of all ages caused by: tobacco smoke, air pollution, occupational dust/fumes, long-term asthma COPD limits pulmonary airflow that is not fully reversible U
Slide 15: Global Initiatives
For personal use only Global Initiatives Global COPD • World Health Organization (WHO) treatment market No candidates in • COPD Foundation US$14 billion (2017) & projected to late stage • American Thoracic Society increase at CAGR development • Centers for Disease Control & Prevention (CDC) >4% to 2
Slide 16: Introducing DMX-700 for COPD
Introducing DMX-700 for COPD * DMX-700 for the treatment of COPD by blocking heteromer signalling in receptors active in COPD ¢ Initial studies on the receptor pair have been conducted under an Innovation Connections grant awarded to Dimerix in November 2018 * The two molecules working together, eac
Slide 17: For personal use only
For personal use only cell cell cell cell 15
Slide 18: DMX-700 pre-clinical data
DMX-700 pre-clinical data 0.644 - wy 4 oa 3 8 0.44 S z > © Both ligands < © A Ligand2 2 o24 : Ligand 1 0.0L sit 0 20 40 Time (min) | Ligand administered @ Dimerix When both Receptor ligands administered More than additive signal observed When only Receptor 2 ligand administered: larger signal observ
Slide 19: For personal use only
For personal use only
Slide 20: A hot area for big pharma?
A hot area for big pharma? <4 Little innovation in new therapies in either kidney or lung disease for over 15 years: 4 w4 long and challenging clinical endpoints no longer required 4 acceptance of surrogate endpoints ¥ Big pharma: more licensing and M&A activity in areas with recent FDA guidance cha
Slide 21: End of Presentation
DIMERIX (ASX:DXB) End of Presentation @ Dimerix